Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Comment by GameChangerBeton May 17, 2021 3:32pm
319 Views
Post# 33215626

RE:The most interesting

RE:The most interesting
bigmack1 wrote: Antibe is the most boring exciting stock in the TSX, but its a tinder box. The slightest volume would send it skyward quickly. Let's see what tomorrow brings. 


Well that's just it, it's a basic function of supply and demand.
On any significant material positive development, you're going to see a strong spike for that very reason.
There will be a substantial amount of demand for the stock, without adequate supply to satisfy it.
That's the general concept. It's amplified particularily more so in Antibe's case.

You got a taste of this when the stock ran up to $7.50 on the announcement of the Nuance deal. There was substantially less supply to satisfy the large influx of demand.
The diference next time is that there are no known events to strike the price back down, i.e equity raises, dillution. 
The next uptick should be able to gain strong momentum and sustain itself, and increase over time after the intial large spike up.
<< Previous
Bullboard Posts
Next >>